

A detailed 3D anatomical illustration of a human spine, showing the vertebrae and intervertebral discs in shades of orange, red, and purple. The spine is shown in a slightly curved, side-on view, with the vertebrae appearing as interconnected blocks and the discs as the spaces between them. The background is a soft, warm gradient of orange and yellow.


HuSignature™

Stratify patients that may benefit from your therapy


Discover and validate genetic signatures of response leveraging the extensive HuPrime® patient-derived xenograft (PDX) model collection.

Use **HuSignature** to find models that match your genetic signatures of interest, or responder and non-responder populations. All from a richly diverse collection of human surrogate PDX models, available for immediate drug discovery efficacy studies.


- Determine or validate relevant gene signatures or pathways related to response.
- Perform “Phase II-like” mouse clinical trials (**HuTrial**) to stratify patient responders and non-responders.
- Characterize potential biomarkers of response.
- Identify novel indications for existing drugs.
- Manage life cycle of existing treatments.
- Constantly growing diverse collection of PDX with patient-relevant mutations.



KRAS Mutation vs Activating Oncogenic Alleles for Cetuximab Sensitivity in CRC PDX Models



Per KRAS codons 12/13 mutation rule: wild type vs mutations.



Per the set of oncogenic alleles rule: wild type/KRAS G13D vs at least one activating allele on KRAS G12C/D/V, -Q61X, -A146T, NRAS Q61X, AKT1 L52R, PIK3CA E545K/-Q546L and BRAF V600E.

Get in touch



Sales

US: +1 858 622 2900

UK: +44 870 166 6234

busdev@crownbio.com

www.crownbio.com



Science

consultation@crownbio.com

